I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Age Related Macular Degeneration

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Feb 12 / Roche and Genentech
Surgical Video Analysis in PDS clinical trials: Lessons learned
This presentation describes the previous use of systematic video review in the Port Delivery Platform with ranibizumab (PDS) clinical development program to inform updates to the PDS procedures and reduce the risk of adverse events. Systematic reviews are now performed in the ongoing Port Delivery Platform development program to proactively identify opportunities for continuous improvement, where warranted.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 9 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries/regions. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.

Sign up or login to unlock the full suite of MEDICALLY features

Jan 21 / Roche and Genentech
Real-World Clinical Outcomes Update in Patients With Neovascular Age-Related Macular Degeneration in the US: The FARETINA-AMD Study
This presentation describes results from the FARETINA-AMD study which is a retrospective real world study using data from the IRIS registry (USA). Data were analyzed February 2022 - March 2023 to identify faricimab▼ starts among patients diagnosed with DME and with at least 12 months of treatment with faricimab▼. Results show vision and anatomic improvement in treatment-naïve eyes and stable vision and anatomic improvement in previously treated eyes. Fewer injections were observed from 6 months onwards, suggesting treatment interval extension.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 19 / Roche and Genentech
Technical Updates to Port Delivery System With Ranibizumab (PDS) for the Treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR)
This presentation provides an update of component-level changes and manufacturing process improvements to the Port Delivery System with ranibizumab (PDS), which provide high confidence of long-term performance of the PDS.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 19 / Roche and Genentech
Characterisation of Fibrosis in the Archway Trial: The Impact of Continuous Delivery of Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
This presentation reports data from a post hoc analysis investigating the incidence of subretinal fibrosis, and it’s correlation to vision outcomes, in patients with nAMD receiving the Port Delivery System with ranibizumab (PDS) or intravitreal ranibizumab in the Archway trial.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 19 / Roche and Genentech
The Clinical Impact of Continuous Delivery of Ranibizumab With the Port Delivery System (PDS) in Neovascular Age-Related Macular Degeneration (nAMD)
This presentation reports the impact of continuous drug delivery via PDS in maintaining long-term vision and retinal anatomy in patients with nAMD.
Upcoming Congresses
Access to Roche and Genentech's medical information
View related congresses

Ask a question or share feedback